• In early January 2026, Ardelyx received a complete dismissal of a securities class action lawsuit and reported past-year commercial progress for IBSRELA, including 73% revenue growth versus 2024, initiation of a Phase 3 trial in chronic idiopathic constipation, and an allowed patent extending protection for IBSRELA and XPHOZAH.
• Together, the legal win and enhanced intellectual property coverage reduce litigation uncertainty while reinforcing the commercial and pipeline potential of Ardelyx’s tenapanor-based portfolio.
• Next, we’ll examine how the lawsuit dismissal and extended patent protection may influence Ardelyx’s existing investment narrative and risk profile.

Outshine the giants: these 28 early-stage AI stocks could fund your retirement.

Ardelyx Investment Narrative Recap

To own Ardelyx, you have to believe in the long term value of its tenapanor franchise, despite reliance on just two commercial products and ongoing reimbursement uncertainty. The lawsuit dismissal and added patent protection reduce legal overhang, but they do not change the near term central catalyst, which is execution on IBSRELA growth, nor the key risk around payer access and Medicare exposure for XPHOZAH.

The newly allowed patent covering IBSRELA and XPHOZAH is especially relevant here, because it helps protect Ardelyx’s concentrated revenue base while the company works to expand tenapanor into chronic idiopathic constipation and deepen uptake in existing indications. That extra IP runway supports the existing catalyst around product life cycle extension, but it does not remove the underlying dependence on favorable reimbursement and market access decisions.

Yet investors should be aware that heavy reliance on a narrow tenapanor product set leaves Ardelyx especially sensitive to...

Ardelyx's narrative projects $704.6 million revenue and $178.8 million earnings by 2028. This requires 22.2% yearly revenue growth and a $235.2 million earnings increase from -$56.4 million today.

Uncover how Ardelyx's forecasts yield a $12.30 fair value, a 76% upside to its current price.

Exploring Other Perspectives

Twelve members of the Simply Wall St Community currently value Ardelyx between US$8 and about US$68, highlighting very different expectations for the business. When you set those views against Ardelyx’s dependence on just two tenapanor products, it underlines why understanding both reimbursement risk and product concentration is critical before forming your own opinion.

Explore 12 other fair value estimates on Ardelyx - why the stock might be worth over 9x more than the current price!

Build Your Own Ardelyx Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Ardelyx research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ardelyx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ardelyx's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 39 companies in the world exploring or producing it. Find the list for free.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.